Factors contributing to the efficacy of two add-on therapies of fesoterodine or mirabegron to silodosin monotherapy for persistent overactive bladder in men with lower urinary tract symptoms

被引：2
|
作者：
Matsukawa, Yoshihisa [1 ]
Gotoh, Momokazu [1 ]
机构：
[1] Nagoya Univ, Dept Urol, Grad Sch Med, Nagoya, Aichi, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2020年 / 27卷 / 01期
关键词：
D O I：
10.1111/iju.14117
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [41] Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study
    Burnett, Arthur L.
    Walker, David R.
    Feng Qi
    Johnston, Karissa M.
    Lozano-Ortega, Greta
    Nimke, David
    Hairston, John C.
    NEUROUROLOGY AND URODYNAMICS, 2020, 39 (05) : 1378 - 1386
  • [42] ESTIMATING THE QUALITY OF LIFE IMPACTS OF TOLTERODINE AND TAMSULOSIN TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER
    Verheggen, B. G.
    Treur, M. J.
    Heeg, B. M. S.
    Botteman, M. F.
    Van Hout, B. A.
    Trocio, J. N.
    VALUE IN HEALTH, 2008, 11 (06) : A655 - A655
  • [43] Effects of tolterodine extended release and/or tamsulosin on bladder diary variables in men with lower urinary tract symptoms including overactive bladder
    Kaplan, Steven A.
    Rovner, Eric S.
    Sussman, David O.
    Kreder, Karl
    Carlsson, Martin
    Bavendam, Tamara
    Guan, Zhonghong
    JOURNAL OF UROLOGY, 2007, 177 (04): : 512 - 513
  • [44] Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS) REPLY
    不详
    JOURNAL OF UROLOGY, 2020, 203 (06): : 1171 - 1171
  • [45] The Efficacy of Mirabegron Additional Therapy for Lower Urinary Tract Symptoms after Treatment with A1-Adrenergic Receptor Blocker Monotherapy: Prospective Analysis of Elderly Men
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2016, 196 (06): : 1711 - 1711
  • [46] The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men
    Tomohiro Matsuo
    Yasuyoshi Miyata
    Katsura Kakoki
    Miki Yuzuriha
    Akihiro Asai
    Kojiro Ohba
    Hideki Sakai
    BMC Urology, 16
  • [47] The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men
    Matsuo, Tomohiro
    Miyata, Yasuyoshi
    Kakoki, Katsura
    Yuzuriha, Miki
    Asai, Akihiro
    Ohba, Kojiro
    Sakai, Hideki
    BMC UROLOGY, 2016, 16
  • [48] RISK FACTORS FOR FAILED DUTASTERIDE ADD-ON TREATMENT TO ALPHA ADRENERGIC ANTAGONISTS FOR PATIENTS WITH LOWER URINARY TRACT SYMPTOMS
    Wada, Naoki
    Ishikawa, Mayumi
    Abe, Noriyuki
    Miyauchi, Kotona
    Makino, Shogo
    Kakizaki, Hidehiro
    JOURNAL OF UROLOGY, 2021, 206 : E486 - E486
  • [49] Comparison of Efficacy and Safety of a Combination of Tamsulosin and Mirabegron versus Tamsulosin Alone in the Management of Overactive Bladder in Males with Lower Urinary Tract Symptoms - TAME-Overactive Bladder: An Open-labeled Randomized Controlled Trial
    Anwar, Azhar
    Gorka, Vivek
    Chahal, Harmandeep Singh
    Sharma, Sandeep
    Tandon, Sunit
    Singhal, Naman
    Narwade, Pankaj Chandrakant
    Chauhan, Nikhil
    Bansal, Namita
    Kaur, Simran
    INTERNATIONAL JOURNAL OF APPLIED AND BASIC MEDICAL RESEARCH, 2023, 13 (04) : 218 - 223
  • [50] Clinical Efficacy and Safety of Imidafenacin as Add-on Treatment for Persistent Overactive Bladder Symptoms Despite α-Blocker Treatment in Patients With BPH: The ADDITION STUDY
    Takeda, Masayuki
    Nishizawa, Osamu
    Gotoh, Momokazu
    Yoshida, Masaki
    Takahashi, Satoru
    Masumori, Naoya
    UROLOGY, 2013, 82 (04) : 887 - 893
12345